Delta opioid receptor as an attractive target for the development of novel psychotropic drug.

DOI Web Site
  • Saitoh Akiyoshi
    Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry
  • Yamada Mitsuhiko
    Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry

Bibliographic Information

Other Title
  • 情動制御におけるオピオイドδ受容体の役割と創薬への可能性
  • ジョウドウ セイギョ ニ オケル オピオイドdジュヨウタイ ノ ヤクワリ ト ソウヤク エ ノ カノウセイ

Search this article

Description

Delta opioid receptor (DOP) agonists have been proposed as attractive candidates for the novel psychotropic drugs. Recently, we have demonstrated that a DOP agonist, KNT-127, shows clear anxiolytic-like effects in rat models of innate anxiety, without memory impairment, motor coordination deficits, or ethanol interactions. We have also demonstrated that KNT-127 shows clear antidepressant-like effects in rats. In addition, KNT-127 produces no convulsive effect and does not impair spatial memory. Therefore, we proposed that DOP should be considered as an attractive target for the development of novel psychotropic drug.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top